Sanofi Statistics
Total Valuation
Sanofi has a market cap or net worth of $95.70 billion. The enterprise value is $115.26 billion.
| Market Cap | 95.70B |
| Enterprise Value | 115.26B |
Important Dates
The next confirmed earnings date is Friday, October 30, 2026, before market open.
| Earnings Date | Oct 30, 2026 |
| Ex-Dividend Date | May 4, 2026 |
Share Statistics
Sanofi has 1.20 billion shares outstanding. The number of shares has decreased by -2.54% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.20B |
| Shares Change (YoY) | -2.54% |
| Shares Change (QoQ) | -0.63% |
| Owned by Insiders (%) | 0.02% |
| Owned by Institutions (%) | 42.88% |
| Float | 1.08B |
Valuation Ratios
The trailing PE ratio is 21.16 and the forward PE ratio is 8.10.
| PE Ratio | 21.16 |
| Forward PE | 8.10 |
| PS Ratio | 1.71 |
| Forward PS | 1.93 |
| PB Ratio | 1.20 |
| P/TBV Ratio | 9.39 |
| P/FCF Ratio | 8.51 |
| P/OCF Ratio | 7.21 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 7.45, with an EV/FCF ratio of 10.24.
| EV / Earnings | 25.49 |
| EV / Sales | 2.06 |
| EV / EBITDA | 7.45 |
| EV / EBIT | 9.75 |
| EV / FCF | 10.24 |
Financial Position
The company has a current ratio of 0.99, with a Debt / Equity ratio of 0.34.
| Current Ratio | 0.99 |
| Quick Ratio | 0.49 |
| Debt / Equity | 0.34 |
| Debt / EBITDA | 1.71 |
| Debt / FCF | 2.39 |
| Interest Coverage | 17.08 |
Financial Efficiency
Return on equity (ROE) is 5.71% and return on invested capital (ROIC) is 9.12%.
| Return on Equity (ROE) | 5.71% |
| Return on Assets (ROA) | 5.09% |
| Return on Invested Capital (ROIC) | 9.12% |
| Return on Capital Employed (ROCE) | 10.66% |
| Weighted Average Cost of Capital (WACC) | 4.96% |
| Revenue Per Employee | $746,710 |
| Profits Per Employee | $60,416 |
| Employee Count | 74,846 |
| Asset Turnover | 0.39 |
| Inventory Turnover | 1.25 |
Taxes
In the past 12 months, Sanofi has paid $1.37 billion in taxes.
| Income Tax | 1.37B |
| Effective Tax Rate | 23.16% |
Stock Price Statistics
The stock price has decreased by -18.50% in the last 52 weeks. The beta is 0.28, so Sanofi's price volatility has been lower than the market average.
| Beta (5Y) | 0.28 |
| 52-Week Price Change | -18.50% |
| 50-Day Moving Average | 42.77 |
| 200-Day Moving Average | 44.72 |
| Relative Strength Index (RSI) | 36.78 |
| Average Volume (20 Days) | 3,334,565 |
Short Selling Information
The latest short interest is 10.61 million, so 0.89% of the outstanding shares have been sold short.
| Short Interest | 10.61M |
| Short Previous Month | 9.30M |
| Short % of Shares Out | 0.89% |
| Short % of Float | 0.98% |
| Short Ratio (days to cover) | 4.33 |
Income Statement
In the last 12 months, Sanofi had revenue of $55.89 billion and earned $4.52 billion in profits. Earnings per share was $1.86.
| Revenue | 55.89B |
| Gross Profit | 41.05B |
| Operating Income | 11.82B |
| Pretax Income | 5.94B |
| Net Income | 4.52B |
| EBITDA | 15.47B |
| EBIT | 11.82B |
| Earnings Per Share (EPS) | $1.86 |
Balance Sheet
The company has $7.25 billion in cash and $26.93 billion in debt, with a net cash position of -$19.68 billion or -$16.43 per share.
| Cash & Cash Equivalents | 7.25B |
| Total Debt | 26.93B |
| Net Cash | -19.68B |
| Net Cash Per Share | -$16.43 |
| Equity (Book Value) | 79.48B |
| Book Value Per Share | 66.00 |
| Working Capital | -466.13M |
Cash Flow
In the last 12 months, operating cash flow was $13.27 billion and capital expenditures -$2.02 billion, giving a free cash flow of $11.25 billion.
| Operating Cash Flow | 13.27B |
| Capital Expenditures | -2.02B |
| Depreciation & Amortization | 3.58B |
| Net Borrowing | -247.71M |
| Free Cash Flow | 11.25B |
| FCF Per Share | $9.39 |
Margins
Gross margin is 73.45%, with operating and profit margins of 21.16% and 8.09%.
| Gross Margin | 73.45% |
| Operating Margin | 21.16% |
| Pretax Margin | 10.62% |
| Profit Margin | 8.09% |
| EBITDA Margin | 27.68% |
| EBIT Margin | 21.16% |
| FCF Margin | 20.52% |
Dividends & Yields
This stock pays an annual dividend of $1.76, which amounts to a dividend yield of 4.44%.
| Dividend Per Share | $1.76 |
| Dividend Yield | 4.44% |
| Dividend Growth (YoY) | 10.40% |
| Years of Dividend Growth | 2 |
| Payout Ratio | 94.66% |
| FCF Payout Ratio | 18.76% |
| Buyback Yield | 2.54% |
| Shareholder Yield | 6.97% |
| Earnings Yield | 4.72% |
| FCF Yield | 11.76% |
Analyst Forecast
The average price target for Sanofi is $53.61, which is 34.80% higher than the current price. The consensus rating is "Buy".
| Price Target | $53.61 |
| Price Target Difference | 34.80% |
| Analyst Consensus | Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (3Y) | 4.45% |
| EPS Growth Forecast (3Y) | 7.97% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 6 |